Mr. Nolan has served as a Director since January 2023. Mr. Nolan serves as the Chief Executive Officer of Jaguar Gene Therapy, a biotechnology company with a mission to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. Prior to this, Mr. Nolan served as General Manager of AveXis, Inc., a clinical stage biopharmaceutical company which developed one of the first gene therapies approved by the FDA for spinal muscular atrophy and was acquired by Novartis Gene Therapies for $8.7 billion. From 2001 to 2018 Mr. Nolan held leadership positions to support global licensing, marketing, business development, and commercialization at Abbott Laboratories, Takeda Pharmaceuticals, Lundbeck, Marathon Pharmaceuticals, Eversana, and KJE Health Pharma Science. Mr. Nolan holds an M.B.A. in Marketing from the University of Notre Dame and a B.S. in Finance from Tulane University.
Mr. Nolan's extensive experience provides unique business development and marketing expertise to the Board, including an understanding of specialty pharma marketing and sales, acquisitions, product launches, recruiting, training, and developing teams, and market access strategy.
Independent Director